Albinism: Clinical Trials

9 trials for Albinism, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

9 completed. 9 Phase 2, 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 29Completed 9
Phase 13Completed 3

Follow Albinism: new trials by email Literature Review of Albinism trials Research Report on Albinism

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.
ponatinib hydrochloride, laboratory biomarker analysis - Malignant Neoplasm
Phase 2CompletedSameek Roychowdhury222015-02-242025-03-24
Immune Disorder HSCT Protocol
Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan - Immune Deficiency Disorders, Severe Combined Immunodeficiency
Phase 2CompletedWashington University School of Medicine282013-04-292026-10-27
Nitisinone for Type 1B Oculocutaneous Albinism
Nitisinone - Albinism, Vision Loss
Phase 1 / Phase 2CompletedNational Eye Institute (NEI)52013-04-162019-02-26
Trial of L-DOPA as a Treatment to Improve Vision in Albinism
Levodopa, Placebo - Albinism
Phase 2CompletedUniversity of Minnesota452010-09-012018-05-02
Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells
Hematopoietic stem cell transplantation - Sickle Cell Disease, Thalassemia
Phase 1 / Phase 2CompletedChildren's Hospital Los Angeles252008-08-012016-06-23
Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome
Pirfenidone, Placebo - Albinism, Inborn Errors of Metabolism
Phase 2CompletedWilliam Gahl, M.D.352005-09-012017-10-16
A Study of Imatinib With Reinduction Chemotherapy Using Mitoxantrone, Etoposide and Cytarabine in Patients With Relapsed/Refractory C-kit Positive (AML) Acute Myeloid Leukemia
Imatinib (Gleevec) - Leukemia
Phase 1 / Phase 2CompletedUniversity Health Network, Toronto352004-07-012015-06-24
Stem Cell Transplant for Immunologic or Histiocytic Disorders
Stem Cell Transplant, Fludarabine, Melphalan - Hemophagocytic Lymphohistiocytosis, X-Linked Lymphoproliferative Disorders
Phase 2CompletedMasonic Cancer Center, University of Minnesota192002-08-012017-12-28
A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Gene
Imatinib mesylate - Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumor (GIST)
Phase 2CompletedNovartis Pharmaceuticals1482000-06-012014-08-19

Narrower conditions

Chediak-Higashi Syndrome (3)  ·  Lymphoproliferative Disorders (3)  ·  Piebaldism (3)  ·  Granulomatous Disease, Chronic (2)  ·  Hyper-IgM Immunodeficiency Syndrome (2)  ·  Immunologic Deficiency Syndromes (2)  ·  Lymphohistiocytosis, Hemophagocytic (2)  ·  Wiskott-Aldrich Syndrome (2)  ·  Albinism, Oculocutaneous (1)  ·  Anemia (1)  ·  Anemia, Dyserythropoietic, Congenital (1)  ·  Anemia, Sickle Cell (1)  ·  Autoimmune Lymphoproliferative Syndrome (1)  ·  Bruton type agammaglobulinemia (1)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (9)  ·  Eye Diseases, Hereditary (9)  ·  Genetic Diseases, Inborn (8)  ·  Metabolic Diseases (8)  ·  Nutritional and Metabolic Diseases (8)  ·  Skin and Connective Tissue Diseases (7)  ·  Amino Acid Metabolism, Inborn Errors (6)  ·  Eye Diseases (6)  ·  Hypopigmentation (6)  ·  Metabolism, Inborn Errors (6)  ·  Pigmentation Disorders (6)  ·  Skin Diseases (6)  ·  Skin Diseases, Genetic (6)  ·  Hematologic Diseases (5)

Interventions

Imatinib Mesylate (2)  ·  Melphalan (2)  ·  fludarabine (2)  ·  Alemtuzumab (1)  ·  Antilymphocyte Serum (1)  ·  Cyclosporine (1)  ·  Hematopoietic Stem Cell Transplantation (1)  ·  Immunoglobulins, Intravenous (1)  ·  Levodopa (1)  ·  Mycophenolic Acid (1)  ·  Stem Cell Transplantation (1)  ·  Thiotepa (1)  ·  fludarabine phosphate (1)  ·  nitisinone (1)  ·  pirfenidone (1)

Sponsors

Children's Hospital Los Angeles (1)  ·  Masonic Cancer Center, University of Minnesota (1)  ·  National Eye Institute (NEI) (1)  ·  Novartis Pharmaceuticals (1)  ·  Sameek Roychowdhury (1)  ·  University Health Network, Toronto (1)  ·  University of Minnesota (1)  ·  Washington University School of Medicine (1)  ·  William Gahl, M.D. (1)

Countries

United States (8)  ·  Australia (1)  ·  Canada (1)  ·  Finland (1)

Top investigators

Angela Smith, MD (1)  ·  Brian P Brooks, M.D. (1)  ·  Gail Summers, M.D. (1)  ·  Hisham Abdel-Azim, MD (1)  ·  Sameek Roychowdhury, MD, PhD (1)

Results publications

PMID 30674731, PMID 31599480